Lilly’s New Obesity Pill Off to Slow Start in Race With Novo
(Bloomberg) — Eli Lilly & Co.’s new weight-loss pill Foundayo has gotten off to a sluggish start, according…
A Monthly Weight Loss Shot? Why Pfizer Could Topple Lilly’s and Novo’s GLP-1 Duopoly
You probably already know that pharmaceutical powerhouses Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) dominate the…
Why Eli Lilly Is Leaving Novo Nordisk in the Dust
Three years ago, Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) had about the same market value.…
Wegovy-maker Novo Nordisk partners with OpenAI to speed drug development
By Maggie Fick LONDON, April 14 (Reuters) – Danish drugmaker Novo Nordisk, which has fallen behind Eli Lilly…
Wegovy-maker Novo Nordisk partners with OpenAI to speed drug development
By Maggie Fick LONDON, April 14 (Reuters) – Danish drugmaker Novo Nordisk, which has fallen behind Eli Lilly…
Novo Nordisk withstands stiff generic competition post semaglutide patent expiry in India in March, 26 brands from 13 firms launched
Danish drug major Novo Nordisk seems to be withstanding stiff competition from generic players after its global blockbuster…
India’s GLP-1 Market Heats Up: Novo Nordisk Faces Generics
Novo Nordisk’s globally recognized diabetes and weight-loss drug, semaglutide, has entered a new competitive phase in India following…
Novo Nordisk partners with OpenAI to speed drug discovery
The race to develop the next generation of medicines just got faster. At least, that is the bet…
Wegovy-maker Novo Nordisk partners with OpenAI to speed drug development
By Maggie Fick LONDON, April 14 (Reuters) – Danish drugmaker Novo Nordisk, which has fallen behind Eli Lilly…
Lilly launches GLP-1 pill, kicking off showdown with Novo Nordisk
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free…
Which of These Healthcare Stocks Is More Likely to Be a Millionaire Maker?
Key Points These two companies operate in a high-growth market, one that’s heading toward $100 billion, according to…
Eli Lilly’s Mounjaro loses ground to Novo Nordisk’s semaglutide, and the slew of cheaper generics
A Mounjaro injection used for weight loss procedures at a clinic in Mumbai, March 31, 2026. | Photo…